Astrazeneca (AZN) Cash & Equivalents (2016 - 2026)

Astrazeneca has reported Cash & Equivalents over the past 17 years, most recently at $7.6 billion for Q1 2026.

For Q1 2026, Cash & Equivalents rose 44.55% year-over-year to $7.6 billion; the TTM value through Mar 2026 reached $7.6 billion, up 44.55%, while the annual FY2025 figure was $5.7 billion, 370.04% up from the prior year.
Cash & Equivalents for Q1 2026 was $7.6 billion at Astrazeneca, up from $5.7 billion in the prior quarter.
Over five years, Cash & Equivalents peaked at $8.1 billion in Q3 2025 and troughed at $1.2 billion in Q4 2024.
A 5-year average of $5.8 billion and a median of $5.8 billion in 2022 define the central range for Cash & Equivalents.
Biggest five-year swings in Cash & Equivalents: crashed 79.2% in 2024 and later surged 370.04% in 2025.
Year by year, Cash & Equivalents stood at $6.2 billion in 2022, then decreased by 5.29% to $5.8 billion in 2023, then crashed by 79.2% to $1.2 billion in 2024, then surged by 370.04% to $5.7 billion in 2025, then skyrocketed by 32.38% to $7.6 billion in 2026.
Business Quant data shows Cash & Equivalents for AZN at $7.6 billion in Q1 2026, $5.7 billion in Q4 2025, and $8.1 billion in Q3 2025.

Peer Comparison